×
The Standard Group Plc is a multi-media organization with investments in media platforms spanning newspaper print operations, television, radio broadcasting, digital and online services. The Standard Group is recognized as a leading multi-media house in Kenya with a key influence in matters of national and international interest.
  • Standard Group Plc HQ Office,
  • The Standard Group Center,Mombasa Road.
  • P.O Box 30080-00100,Nairobi, Kenya.
  • Telephone number: 0203222111, 0719012111
  • Email: [email protected]

Rolling malaria from the face of the Earth

Health & Science

LONDON, Wednesday

After 23 years of painstaking laboratory work and a programme of major trials in seven countries, US-Italian biologist, Joe Cohen 67, says the clinical case for the vaccine is almost proved.

It’s a breakthrough that could save hundreds of thousands of lives, but when it comes to public health in the developing world, Cohen knows hard science is only half the job.

That’s why the softly spoken researcher found himself one chilly December evening pitching his life’s work to rich-world politicians whose voters will have to foot the bill, and fielding questions over festive mince pies and wine in a leather and oak-clad room in London’s Houses of Parliament.

How cost-effective will the vaccine be compared to tried and tested low-tech approaches like mosquito nets and insecticides, one person asks.

Is there any evidence that it will bring down the spread of the disease in general, helping those who haven’t been vaccinated? How long is a shot likely to stay effective? Is there a danger it might foster a false sense of security?

As the session goes on, it’s clear that enthusiasm for Cohen’s work is coupled with wariness among the experts and well-informed lawmakers.

The bottom-line question: Is the vaccine — and global health community’s aim of completely eradicating a disease that kills a child every 45 seconds — really worth the money?

It may seem an absurd thing to ask. Malaria threatens half the people on the planet and kills around 800,000 people a year, many of them too young to have even learned to walk.

The death rate has come down in the last decade, but full-scale eradication will cost billions and drag funds away from other equally, or possibly even more urgent health efforts.

As governments in poor countries and donors from wealthy ones weigh up where to put their money, experts have begun a quiet but fundamental debate about whether wiping out malaria is realistic or even makes economic sense.

"With all of the money and human capacity in the world, there is very little doubt that we could eliminate malaria. The question is: What is the best value for our dollar? And this is an increasingly pressing question as we look at the global economic climate," says malaria expert Oliver Sabot, who works at the Clinton Health Access Initiative in Boston.

Mud-and-thatch

What is the best value for our dollar? The answer to that question seems obvious to someone like Loyce Dama Karisa, a Kenyan woman who recently gave birth to her seventh child, a girl called Rehema. Karisa has come in a minibus full of other mothers and babies to a clinic in the mud-and-thatch village of Madamani in Kilifi District.

GlaxoSmithKline (GSK), the British-based drugmaker that Cohen works for, is using the clinic as part of Africa’s biggest ever medical experiment, giving the vaccine to babies and young children in a trial designed to assess its efficacy. "I wanted my child to get this vaccine," Karisa says. "Malaria is a very bad disease."

In the Kilifi District Hospital, the children’s high-dependency unit is full of malaria patients. Listless babies and toddlers lie motionless in adult-sized beds, tangles of tubes taped to their nostrils, arms and legs. One boy has his hands bandaged into stumps to stop him pulling a tube out of his nose.

He screams and thrashes about as a drip is attached to a vein in his foot. Mothers in mint green hospital gowns watch silently. One cradles her tiny sleeping baby’s hand in her own while a ceiling fan chops slowly through the hot air, doing nothing to reduce the draining heat.

Families in Kilifi, which despite its lush green vegetation has poor soil for growing crops and high levels of poverty, are almost numb to the ravages of malaria. It’s a similar story across the continent: around 90 percent of malaria’s victims live in sub-Saharan Africa; most of those are under five.

The disease is caused by a parasite carried in the saliva of mosquitoes.

GSK’s vaccine goes to work at the point the parasite enters the human bloodstream after a mosquito bite. By stimulating an immune response, it can prevent the parasite from maturing and multiplying in the liver.

Without that response, the parasite re-enters the bloodstream and infects red blood cells, leading to fever, body aches and in some cases death.

– Reuters

 

Related Topics


.

Trending Now

.

Popular this week